Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cannabinoids decrease acetylcholine release in the medial-prefrontal cortex and hippocampus, reversal by SR 141716A

G L Gessa1, M A Casu, G Carta

  • 1B.B. Brodie Department of Neuroscience, University of Cagliari, Italy. lgessa@unica.it

European Journal of Pharmacology
|October 6, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology.

NPJ Parkinson's disease·2023
Same author

Localized waves in elastic plates with perturbed honeycomb arrays of constraints.

Philosophical transactions. Series A, Mathematical, physical, and engineering sciences·2022
Same author

Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology.

NPJ Parkinson's disease·2022
Same author

Supercritical extraction of volatile and fixed oils from <i>Petroselinum crispum</i> L. seeds: chemical composition and biological activity.

Natural product research·2020
Same author

How to demystify COVID-19 and reduce social stigma.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020
Same author

Wave polarization and dynamic degeneracy in a chiral elastic lattice.

Proceedings. Mathematical, physical, and engineering sciences·2020
Same journal

Astaxanthin inhibits platelet-mediated thrombosis via suppression of bidirectional αIIbβ3 signaling.

European journal of pharmacology·2026
Same journal

Repurposing of alogliptin to mitigate experimentally-induced ulcerative colitis and its associated pulmonary injury in rats through regulating inflammatory, necroptotic, and ER stress pathways.

European journal of pharmacology·2026
Same journal

Erianin ameliorates liver fibrosis through the PRDX3/NLRX1 axis.

European journal of pharmacology·2026
Same journal

4-Octyl itaconate attenuates renal calculi formation by inhibiting ferroptosis and oxidative stress via the Nrf2-HO-1/SLC7A11 axis.

European journal of pharmacology·2026
Same journal

VER155008 rescues cognitive impairment in P301S tauopathy mice by promoting HSPA8-mediated lipophagy.

European journal of pharmacology·2026
Same journal

Okanin alleviates osteoarthritis by suppressing oxidative stress and pyroptosis via Nrf2/HO-1 activation.

European journal of pharmacology·2026
See all related articles

Delta9-tetrahydrocannabinol (THC) and synthetic cannabinoids inhibit acetylcholine release in the brain, impacting cognitive function. This effect is mediated by CB1 receptors, suggesting antagonists could treat cognitive deficits.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Cannabinoids, including delta9-tetrahydrocannabinol (THC) from marijuana and synthetic agonists like WIN 55,212-2, interact with the brain's endocannabinoid system.
  • Acetylcholine is a key neurotransmitter involved in cognitive processes, and its regulation is crucial for brain function.

Purpose of the Study:

  • To investigate the effects of THC and WIN 55,212-2 on acetylcholine release in the medial-prefrontal cortex and hippocampus.
  • To determine the role of cannabinoid CB1 receptors in mediating these effects.
  • To explore the potential involvement of endogenous cannabinoids in regulating acetylcholine release.

Main Methods:

  • In vivo microdialysis in freely moving rats.
  • Administration of delta9-tetrahydrocannabinol (THC) and WIN 55,212-2.

Related Experiment Videos

  • Administration of the CB1 receptor antagonist SR 141716A.
  • Measurement of acetylcholine output in the medial-prefrontal cortex and hippocampus.

    • Main Results:

    • Both THC and WIN 55,212-2 significantly inhibited acetylcholine release in both brain regions.
    • The inhibitory effects of THC and WIN 55,212-2 were completely blocked by the CB1 antagonist SR 141716A.
    • SR 141716A alone, at higher doses, increased acetylcholine release, indicating tonic inhibition by endogenous cannabinoids.

    Conclusions:

    • Cannabinoid receptor CB1 activation by THC and synthetic agonists reduces acetylcholine release in key brain areas involved in cognition.
    • These findings suggest that the cognitive impairments associated with marijuana use may be linked to cannabinoid-induced suppression of acetylcholine.
    • Cannabinoid receptor antagonists represent a potential therapeutic strategy for addressing cognitive deficits.